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Humphrey Center scientists seek insights 
into the mystery of tumor metastasis 
If tumors didn't spread within the body, 
cancer would be a relatively minor health 
problem. Consider colon cancer. This 
disease, which claims the lives of more 
than 50,000 Americans each year, is 
readily cured if the tumor is removed 
before it has spread beyond the colon's 
inner lining. 
Once the cancer starts to penetrate 
into the colon wall, however, the chances 
of a cure begin to decline. And after it 
has gone through the wall—meaning that 
it can spread to new locations—the 
chances of a cure diminish significantly. 
"The current chemotherapies and 
radiotherapies for treatment of cancer 
leave a good deal of room for 
improvement," says Herbert Z. Kupchik, 
Ph.D., a scientist at the Hubert H. 
Humphrey Cancer Research Center and 
an associate professor of microbiology 
and pathology at Boston University 
School of Medicine. 
Yet the irony of colon cancer, as with 
many other types of cancers, is that very 
few tumor cells have the ability to seed a 
malignancy in a new location. Typically, 
only about 1 tumor cell in 100,000 has 
this capability. 
The fact that the ability to metastasize, 
or spread, is relatively rare raises the 
intriguing possibility of seeking to target 
the few cells in a tumor with the trait. 
Dr. Kupchik and his associates have 
spent several years working to set the 
stage for exactly such a strategy. 
The first step in colon cancer 
metastasis is a process called invasion. 
"An invasive tumor is one that has begun 
to penetrate the bowel wall," notes Dr. 
Kupchik. 
The process starts when some cells 
break away from the main tumor mass 
and begin to squeeze through the bowel 
wall. These cells lead the invasive front. 
As the tumor penetrates the wall, 
eventually more cells will follow. 
To isolate cells with a tendency to 
grow in this way. Dr. Kupchik and his 
associates needed to mimic the barriers 
facing a tumor. They chose a tissue 
called the amnion, a part of the placenta, 
for the role. 
Collagen-cancer links 
to pinpoint the nature 
Collagen, though but one among the 
many thousands of types of proteins in 
our bodies, does have some distinctive 
traits. 
For one thing, it's one of the most 
common of all our proteins. For another, 
it's a major component of many of the 
tissues—tendons, bones, the skin—that 
determine the way our bodies are put 
together. 
Besides being a key structural protein, 
collagen also has numerous connections 
witli cancer. For example, it's the main 
constituent of the coatings that sometimes 
form around tumors, says Barbara D. 
Smith, Ph.D., a Hubert H. Humphrey 
Cancer Research Center scientist and an 
"We obtained cells from a tumor that 
was already invasive before it was 
removed," says Dr. Kupchik. "Then, we 
did a series of experiments to see if we 
could identify a subset of these cells that 
could penetrate the amnion." 
The reseachers were able to isolate a 
group of cells that were more invasive by 
nature than other cells from the same 
tumor. The key question remained: 
Could they identify traits that set invasive 
cells apart from non-invasive cells? 
In later experiments, the researchers 
found that there is a major difference 
between the two types of cells. The 
invasive cells were much more strongly 
drawn toward laminin—a protein found, 
among other places, in the colon wall's 
continued on back 
may yield ways 
of specifie tumors 
associate professor of biochemistry at 
Boston University School of Medicine. 
"If you have a tumor and your body sees 
it as foreign," says Dr. Smith, "there are 
certain cells that can encapsulate it with 
collagen. These tumors tend to be 
benign more often than those that aren't 
so encapsulated." 
Collagen is also a key part of the tiny, 
web-like structure, called a matrix, that 
exists in the narrow spaces between the 
cells in our bodies. Cancer cells don't 
readily attach to matrices, which may be 
partly why tumors are able to grow so 
rapidly. 
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Tumor metastasis 
continued from front 
outer layer—than the non-invasive cells. 
"We coated the bottom of a filter with 
laminin," says Dr. Kupchik, "and the 
cells that reached it through the filter 
were the invasive ones." 
The discovery, combined with reports 
from other laboratories linking laminin to 
invasion-prone tumor cells, raises the 
prospect of new types of anti-cancer 
strategies. Dr. Kupchik notes that it's 
likely so-called laminin receptors in the 
invasive cells are both stronger and more 
numerous than those in the non-invasive 
cells. If so, it may be possible to attack 
invasive tumor cells by using 
antibodies—substances that home in on a 
specific, target molecule—^to the 
receptors. 
To be fully successful, however, notes 
Dr. Kupchik, such a strategy has to take 
account of the fact that invasive tumor 
cells are drawn to other colon-wall 
proteins besides laminin. An 
anti-laminin approach, he says, "may be 
part of the answer, but not the whole 
answer." 
Collagen cancer 
continued from front 
Dr. Smith's special interest centers on 
the fact that some tumor cells don't make 
normal collagen. Her group has been 
experimenting with liver cancer cells. 
Normal collagen molecules consist of 
three tiny strands wound around each 
other—a sort of microscopic cable—^but 
not the collagen molecules produced by 
the cells she's studying. "In these cells, 
one of the three chains is missing from 
the molecule," says the scientist. 
For certain types of cancer, physicians 
already use a tumor's interactions with 
matrices in judging what specific kind of 
tumor it is—an approach that allows for 
more carefully targeted treatment 
strategies. Eventually, says Dr. Smith, it 
might be possible to use the nature of the 
abnormal collagen made by a tumor to 
fine-tune prognostic judgments. Before 
that can happen, however, there's a need 
for more understanding of cancer's 
effects on coUagen. 
Dr. Smith and her associates have 
been exploring why the cancerous cells 
they're working with make collagen that 
lacks one of the three chains found in the 
normal version of the protein. Knowing 
that an altered gene was the most likely 
explanation, she says, the group "cloned 
the genes from these cells to see if they 
were mutated." 
Through such experiments, the 
researchers were able to pinpoint specific 
segments of DNA that may provide the 
key to the abnormalities in collagen. 
These segments, called promoters and 
enhancers, are part of the gene's 
regulatory machinery. The researchers 
have found that certain types of 
cancer-causing agents can disrupt the 
normal workings of this machinery. 
Currently, the group is seeking to 
confirm their findings through a new 
series of experiments. 
In pursuing their studies of collagen. 
Dr. Smith and her associates are 
following a trail originally laid down by 
the late Sidney Cooperband, M.D., the 
Humphrey Cancer Center's first director. 
Dr. Cooperband's hope, says Dr. 
Smith, was to find ways to boost the 
collagen output of cancerous cells. "He 
felt that if you could increase collagen 
production," she says, "you'd have a 
better chance of walling off the tumor 
and preventing its spread." 
TTiat goal has yet to be achieved, says 
Dr. Smith, and there's no way to predict 
today whether it will turn out to be 
achievable. She also says, however, that 
considering the close links between 
cancerous growth and collagen 
production, there's good reason to hope 
that current studies of how malignancies 
affect collagen will yield at least some 
new methods of aiding cancer patients. 
CANCER NOTES 
CANCER NOTE: About one of every 
10 women in the United States will 
develop breast cancer during her lifetime. 
Until the disease can be prevented, the 
best way women can protect themselves 
is through early detection and prompt 
treatment. Today, with modem 
technologies, breast cancer can be 
detected at very early stages of 
development, when the chance of cure is 
highest. The American Cancer Society 
recommends that women develop a 
three-part, personal plan of action for 
early detection of breast cancer. This 
plan should include a clinical breast 
examination by a doctor, a mammogram 
and breast self-examination. 
CANCER NOTE: Cancer strikes at any 
age. It kills more children ages 3 to 14 
than any other disease, and occurs more 
frequently with advancing age. In the 
1980s, it was estimated there were over 
4.5 million cancer deaths, almost 9 
million new cancer cases, and some 12 
million people under medical care for 
cancer. In 1990, about 1,040,000 people 
will be diagnosed as having cancer. 
CANCER NOTE: Many patients with 
primary bone cancer now are treated 
successfully by removing and replacing a 
section of bone rather than by amputating 
the leg or arm. Dmgs and radiation 
therapy are being used effectively after 
bone cancer surgery, resulting in 
dramatic improvement in survival. 
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